Helix BioPharma Corp. has signed an agreement with KBI Biopharma, Inc. to develop a process for preparing L-DOS47 in a lyophilized (freeze-dried powder) vial format for clinical testing.     “This new arrangement advances the Company closer to its objective of initiating clinical testing with L-DOS47,” said John Docherty, president of Helix. “The lyophilized packaging format will provide for optimum stability of L-DOS47 while in storage so that individual vials may be recons...